Anti-EGFR strategy for colorectal cancer: Searching for the real target

被引：0

作者：

Zaniboni, A. ^{[1
]}

Meriggi, F. ^{[1
]}

机构：

[1] Fdn Poliambulanza, UO Oncol Med, I-25100 Brescia, Italy

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2006年 / 3卷 / 08期

关键词：

cetuximalb; colorectal cancer; anti-EGFR therapy;

D O I：

10.2174/157018006778194673

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable.

引用

页码：541 / 543

页数：3

共 50 条

[31] Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? [J].

Fakih, Marwan .

EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (09) :1471-1480

[32] Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era [J].

Van Cutsem, Eric ;

Tejpar, Sabine .

TARGETED ONCOLOGY, 2008, 3 (04) :223-225

[33] Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies [J].

Lievre, Astrid ;

Laurent-Puig, Pierre .

PERSONALIZED MEDICINE, 2009, 6 (02) :145-157

[34] Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer [J].

Saridaki, Zacharenia ;

Georgoulias, Vassilis ;

Souglakos, John .

WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (10) :1177-1187

[35] Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies [J].

Zhang, Wu ;

Gordon, Michael ;

Lenz, Heinz-Josef .

ANNALS OF MEDICINE, 2006, 38 (08) :545-551

[36] HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer [J].

Huang, Wenbai ;

Chen, Yijiao ;

Chang, Wenju ;

Ren, Li ;

Tang, Wentao ;

Zheng, Peng ;

Wu, Qi ;

Liu, Tianyu ;

Liu, Yu ;

Wei, Ye ;

Xu, Jianmin .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (04) :993-1002

[37] HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer [J].

Wenbai Huang ;

Yijiao Chen ;

Wenju Chang ;

Li Ren ;

Wentao Tang ;

Peng Zheng ;

Qi Wu ;

Tianyu Liu ;

Yu Liu ;

Ye Wei ;

Jianmin Xu .

Journal of Cancer Research and Clinical Oncology, 2022, 148 :993-1002

[38] Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer [J].

Ouwerkerk, Jan ;

Boers-Doets, Christine .

EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2010, 14 (04) :337-349

[39] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer [J].

Jose A. García-Sáenz ;

Javier Sastre ;

Eduardo Díaz-Rubio García .

Clinical and Translational Oncology, 2009, 11 :737-747

[40] The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies [J].

Meriggi, Fausto ;

Vermi, William ;

Bertocchi, Paola ;

Zaniboni, Alberto .

REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (01) :8-12

← 1 2 3 4 5 →